Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Immuneering Corporation (NASDAQ:IMRX) has earned an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $16.50.

A number of equities research analysts recently commented on IMRX shares. Oppenheimer reaffirmed an “outperform” rating on shares of Immuneering in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research note on Friday, March 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Immuneering in a research note on Monday, March 9th. Chardan Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of Immuneering in a research note on Tuesday, May 19th. Finally, Wall Street Zen raised Immuneering from a “sell” rating to a “hold” rating in a research note on Sunday, April 19th.

Immuneering Stock Down 4.7%

Shares of Immuneering stock opened at $4.27 on Friday. Immuneering has a 12 month low of $1.66 and a 12 month high of $10.08. The business has a fifty day simple moving average of $5.28 and a 200 day simple moving average of $5.53. The stock has a market cap of $276.27 million, a PE ratio of -3.65 and a beta of 0.38.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.09. Analysts expect that Immuneering will post -1.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Weiss Asset Management LP bought a new position in Immuneering during the first quarter worth about $464,000. Cetera Investment Advisers bought a new position in Immuneering during the first quarter worth about $67,000. Levin Capital Strategies L.P. bought a new position in Immuneering during the first quarter worth about $53,000. Hsbc Holdings PLC bought a new position in Immuneering during the first quarter worth about $198,000. Finally, Y Intercept Hong Kong Ltd bought a new position in Immuneering during the first quarter worth about $75,000. 67.65% of the stock is currently owned by institutional investors.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.